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The purpose of this study is to develop and improve oral liquids formulations of sildenafil citrate 
for paediatric use. Four different formulations were developed, which are as follows: two aqueous 
solutions of sildenafil citrate (2.5 mg/mL), with or without preservatives, and two other solutions of 
sildenafil in simple syrup (1.25 mg/mL), with or without preservatives. All of the formulations were 
physically, chemically and microbiologically stable for three months. The results of the stability studies 
allowed for the optimisation of formulations without preservatives due to their simplicity and their 
similar stable conditions when compared to the formulations containing antimicrobials. The shelf life 
of both formulations was three months; however, upon opening, aqueous solutions should be used 
within 10 days and kept refrigerated, and syrup solutions should be used within 14 days in a hospital  
setting.
Uniterms: Chemical stability. Microbiological stability. Sildenafil citrate. Paediatric formulations.
O objetivo deste trabalho é desenvolver e otimizar formulações líquidas orais de citrato de sildenafil 
adequadas ao uso pediátrico. Foram desenvolvidas quatro formulações diferentes: duas soluções aquosas 
de citrato de sildenafila (2,5 mg/mL) com ou sem conservantes e duas soluções de citrato de sildenafil em 
xarope simples (1,25 mg/mL) com ou sem conservantes. Todas as formulações desenvolvidas apresentaram 
estabilidade quer físico-química quer microbiológica durante 3 meses. Os resultados dos estudos de 
estabilidade permitiram otimizar as formulações isentas de conservantes, uma vez que estas eram mais 
simples e apresentavam do mesmo modo uma boa estabilidade, comparando com as formulações que 
continham conservantes. O período de utilização de ambas as formulações é de três meses, no entanto, 
após abertura do frasco, a solução aquosa deve ser utilizada durante 10 dias, acondicionada no refrigerador 
e o xarope deve ser utilizado durante 14 dias, mesmo em ambiente hospitalar.
Unitermos: Estabilidade química. Estabilidade microbiológica. Citrato de sildenafil. Formulações 
pediátricas.
INTRODUCTION
The lack of commercially available oral liquid 
dosage forms adequate for paediatric use remains 
a problem in many practice settings. Indeed, many 
medicines used to treat children are either unlicensed or 
are prescribed off-label (Tafuri et al., 2009; Kairuz et al., 
2007). A literature review (Pandolfini, 2005) revealed 
that off-label/unlicensed prescription rates ranged from 
11% to 80%, and higher rates were found in younger 
versus older patients and in hospital versus community 
settings. In paediatric hospital wards, the use of off-label/
unlicensed prescriptions ranged from 16% to 62%, and in 
the community setting, use rates ranged from 11% to 37% 
(Pandolfini, 2005). Up to 90% of medicinal products used 
in neonates are off-label or unlicensed (EMEA, 2009).
Problems resulting from the absence of appropriate 
medicinal products for the paediatric population include 
inadequate dosage information, which leads to an 
increased risk of adverse reactions including death; 
ineffective treatment through under-dosage; inability to 
access therapeutic advances for paediatric populations; 
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lack of suitable formulations; lack of appropriate routes of 
administration; as well as the use of magistral or official 
formulations, which may be of poor quality for the treatment 
of paediatric populations (EMEA, 2006; EU, 2006). A study 
conducted in the United Kingdom showed that 54% of 112 
paediatric extemporaneous formulations had inadequate 
data to guarantee their quality during the period of use 
(Brion, 2003). Many studies have been published with the 
purpose of assessing the extent to which formulations not 
studied in children are used. These studies have increased 
awareness of the need to develop new formulations suitable 
for paediatric use, which take into account the evaluation 
of their quality and stability using adequate stability studies 
(Jong et al., 2002; Schirm, 2003; Grieve et al., 2005; Ceci 
et al., 2006; Ghulam et al., 2007).
An example of an unlicensed and off-label use of a 
medication in children and neonates is the extemporaneous 
preparation of sildenafil citrate from tablets, as a liquid 
preparation of sildenafil citrate is not commercially 
available. Sildenafil citrate has been used to treat 
pulmonary arterial hypertension (PAH) in children and 
neonates. A number of review papers and case reports 
on the use of oral sildenafil citrate as a treatment for 
PAH of different aetiologies in children have been 
published (Fernández-González et al., 2004; García-
Martinez et al., 2003; Humpl et al., 2005; Keller et al., 
2004; Kothari, 2002; Ladha et al., 2005; Leibovitch, 
2007; Namachivayam et al., 2006; Barnett, 2006). These 
published documents demonstrate the efficacy and safety 
of sildenafil citrate in the paediatric population, including 
newborns. Because the only commercially available 
dosage form of sildenafil citrate is tablets, it is important 
to develop a liquid formulation of sildenafil citrate of 
adequate quality and stability to treat the paediatric 
population. Nahata (2006) developed two extemporaneous 
sildenafil citrate oral suspensions from commercial tablets 
using methylcellulose and simple syrup as the vehicle or 
ready-to-use preparations of Ora-Plus and Ora-Sweet. 
However, in these formulations, all of the excipients 
included on the tablets are concomitantly administered 
to children.
Manipulating adult medicine products into paediatric 
forms should be considered a secondary option to be 
performed only when the pure active ingredient is not 
available (EMEA, 2006). Given this, the aim of this study 
was to develop an oral liquid formulation of sildenafil 
citrate, as it is an important drug used in the paediatric 
population, including neonates, for the treatment of PAH. 
The formulations were kept as simple as possible and 
were prepared from pure active ingredients and not from 
commercial tablets, to avoid the potentially undesirable 
adverse effects of excipients (EMEA, 2006; American 
Academy of Pediatrics, 1997).
MATERIAL AND METHODS
Chemical and reagents 
Sildenafil citrate, pure active ingredient (99.2%), Lot 
SDC/0610003, was obtained from Matrix Laboratories 
Limited, Secunderab - India. Methylparaben (99%), lot 
J7646A, and propylparaben (99%), lot D9626A, were 
obtained from Alfa Aesar GmbH, Kalsruhe, Germany. 
Propylenoglycol of analytical grade, lot 437727/1, was 
obtained from Alpha Chemika, Maharashatra India, 
and sucrose, G001, was obtained from SIDUL, Santa 
Iria Azoia, Portugal. Purified water was obtained from 
Millipore system Millipore Corporation Progrard TM®, 
USA.
A solution of methylparaben and propylparaben 
(10%, 7:3, w/v) in propylenoglycol was also used after 
filtration.
Preparation of solutions
Four different solutions were prepared:
1. An aqueous solution of sildenafil citrate 2.5 mg/mL 
containing preservatives
2. An aqueous solution of preservative-free sildenafil 
citrate 2.5 mg/mL
3. A solution of sildenafil citrate 1.25 mg/mL in simple 
syrup containing preservatives
4. A preservative-free solution of sildenafil citrate 
1.25 mg/mL in simple syrup
Three preparations of each formulation were 
prepared. All preparations were stored in well-closed 
60 mL amber, Type III glass bottles, lot nº 266077 
obtained from Saint-Gobain La Grange, Segovia, 
Spain.
Method of preparation used for preservative-free 
aqueous solution sildenafil citrate 2.5 mg/mL
1. The required quantity of each ingredient for a 
250 mL solution to be prepared was calculated.
2. Each ingredient was accurately weighed and/or 
measured.
3. Six hundred twenty-five milligrams of sildenafil 
citrate was dissolved with 250 mL of water in a 
graduated cylinder for 20 minutes under mag-
netic agitation using a 30 ºC water bath, Emílio de 
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Azevedo Campos, Portugal. The final solution was 
filtered.
Method of preparation for aqueous solution 
sildenafil citrate 2.5 mg/mL containing preservatives
1. The required quantity of each ingredient for a 
250 mL solution to be prepared was calculated.
2. Each ingredient was accurately weighed and/or 
measured.
3. 625 mg of sildenafil citrate was dissolved with 
200 mL of water in a 250-mL volumetric flask.
4. A solution of 2.4 mL of methylparaben and propyl-
paraben was added to step 3.
5. Sufficient water was added to obtain a sufficient 
volume.
6. The dissolution was carried out with magnetic 
agitation using a 30 ºC water bath, and the solution 
obtained was filtered.
Method of preparation for a preservative-free 
solution of sildenafil citrate in syrup 1.25 mg/mL
1. The required quantity of each ingredient for a 
250 mL solution to be prepared was calculated.
2. Each ingredient was accurately weighed and/or 
measured.
3. Then, 312.5 mg of sildenafil citrate was dissolved 
in 110 mL of water under magnetic agitation for 
20 minutes using a 30 ºC water bath.
4. 220 g of sucrose was added and dissolved under 
agitation until a limpid solution was obtained and 
was followed by filtration.
Method of preparation for a solution of sildenafil 
citrate in syrup 1.25 mg/mL containing preservatives
1. The required quantity of each ingredient for a 
250 mL solution to be prepared was calculated.
2. Each ingredient was accurately weighed and/or 
measured.
3. Then, 312.5 mg of sildenafil citrate was dissolved 
in 110 mL of water under magnetic agitation for 
20 minutes using a 30 ºC water bath.
4. A solution of 2.4 mL of methylparaben and pro-
pylparaben was added under agitation to complete 
dissolution.
5. 220 g of sucrose was added while maintaining the 




Sample s  we re  checked  fo r  o rgano l ep t i c 
characteristics.
Measurement of pH
The pH was immediate ly  measured in  a l l 
preparations and throughout the stability study (Meter 
pH 526, Multicar®, WTW, Germany).
Sildenafil Citrate Content
Sildenafil citrate content was determined after 
preparation and throughout the stability study using 
ultraviolet-visible (UV-VIS) spectrophotometric method 
at 292 nm (Shimadzu UV-Visible 1603, Shimadzu, Japan). 
The analytical methodology was validated for selectivity, 
linearity, precision, and accuracy. No interference of 
excipients was observed. The linearity of the standard 
curve was determined by linear regression analysis of 
sildenafil citrate concentrations versus absorbance values 
(Figure 1). The correlation factor was 0.999, with intraday 
and interday coefficients of variation of 0.1 and 1.8, 
respectively. The percentage of recovery changed from 
100.6 to 101.4 and 101.1 to 101.8 in the presence of the 
parabens or sucrose, respectively.
Stability studies
Protocols for stability studies have been performed 
according to the Committee for Proprietary Medicinal 
Product’s Guidelines on Stability Testing: Stability Testing 
of Existing Active Substances and Related Finished 
Products10 (CPMP, 2003a).
Chemical stability studies
Twelve sildenafil citrate solutions were prepared. 
FIGURE 1 - Standard curve of determination of Sildenafil Citrate 
Content using the spectrophotometric method.
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Six solutions were aqueous; of these, three contained 
preservatives, and the other three were preservative free. 
Another six solutions were prepared in simple syrup. Of 
these, three were prepared with preservatives, and the 
other three were preservative free. Stability was evaluated 
for three months, during which time the preparations were 
stored in a chamber (Heraeus, Alemanha) under controlled 
conditions at 5 ºC ± 3 ºC and 25 ºC ± 2 ºC /60% RH ± 5% 
RH. Samples were collected at days 0, 7, 14, 28, 42, 56, 
70, and 91. Appearance, pH, and sildenafil citrate content 
were evaluated.
Microbiological stability studies
The microbiological quality of sildenafil citrate 
solutions stored during stability studies was assessed 
according to European Pharmacopoeia (EP, 2005) 
Monograph 5.1.4.—Microbiological Quality of 
Pharmaceutical Preparations. Microbial examination was 
performed by counting total viable aerobic microorganisms 
using the plate-count method based on the EP from 2.6.12. 
Microbial Examination of Non-Sterile Products: Total 
Viable Aerobic Count.
In-use stability
Preservative-free solutions were submitted to in-use 
stability tests, in both hospital and ambulatory conditions, 
for 10 (aqueous solutions) and 14 days (syrup solutions), 
according to the Committee for Proprietary Medicinal 
Product’s Note for Guidance on In-use Stability Testing 
of Human Medicinal Products (CPMP, 2001).
RESULTS
Chemical stability
Aqueous sildenafil citrate solutions, with and 
without preservatives, were limpid, colourless, and 
odourless solutions with a slight bitter taste. Sildenafil 
citrate in simple syrup, with and without preservatives 
was limpid, yellowish, and had a sweet taste. Both 
solutions remained unchanged in appearance at selected 
temperatures throughout the stability study. The pH values 
remained fairly constant without significant changes in 
the preparations (Figures 2, 3). At the end of stability 
studies under 5 ºC ± 3 ºC, the pH of preservative-free 
aqueous solutions was the same as the initial determination 
(pH = 4.02) with no significant changes during study 
determinations (Figure 2). At day 91, the aqueous solutions 
with preservative had the same pH, independent of 
storage conditions; pH values ranged from 3.84 ± 0.15 or 
3.98 ± 0.04 on day 28 and 4.11 ± 0.09 on day 91 (Figure 2).
The pH values of syrup solutions were slightly 
higher than aqueous solutions. In preservative-free 
syrup solutions, pH values changed from 4.27 ± 0.06 
at the beginning of the stability studies to 4.30 ± 0.02 
or 4.26 ± 0.13 at the end of the studies, respectively, at 
5 ºC or 25 ºC (Figure 3). Initially, the pH in the syrup 
solutions containing preservatives was 4.30 ± 0.1, and 
during stability determinations, the values ranged from 
4.22 ± 0.04 to 4.32 ± 0.02 at 5 ºC or between 4.19 ± 0.1 
and 4.34 ± 0.1 at 25 ºC (Figure 3).
Sildenafil Citrate Content
Analytical results show that sildenafil citrate content 
in all preparations remained above 95% (w/v) throughout 
91 days in both conditions (Figures 4, 5). Initially, the 
percentage of sildenafil citrate content in preservative-
free aqueous solutions was 100.75 ± 0.96. At the end of 3 
months, the percentages of sildenafil citrate content were 
100.04 ± 0.52 at 25 ºC and 101.69 ± 1.02 at 5 ºC (Figure 4). 
At day 91, the percentages of sildenafil citrate content in 
solutions with preservative were 101.86 ± 1.30 at 25 ºC 
and 102.97 ± 0.34 at 5 ºC.
The percentages of sildenafil citrate content 
in preservative-free syrup solutions on day 91 were 
99.19 ± 2.75 and 98.97 ± 0.99 at 25 ºC and 5 ºC, 
respectively. In solutions containing preservatives, the 
FIGURE 2 - The pH variation of sildenafil citrate aqueous 
solutions (mean ± standard deviation; n = 3).  preservative-free 
solution stored at 5 ºC ± 3 ºC and  stored at 25 ºC ± 2 ºC/60% 
RH ± 5% RH  solution containing preservative stored at 5 ºC 
± 3 ºC and  stored at 25 ºC ± 2 ºC/60% RH ± 5% RH.
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FIGURE 3 - The pH variation of sildenafil citrate syrup solutions 
(mean ± standard deviation; n = 3).  preservative-free solution 
stored at 5 ºC ± 3 ºC and  stored at 25 ºC ± 2 ºC/60% RH ± 5% 
RH  solution containing preservative stored at 5 ºC ± 3 ºC and 
 stored at 25 ºC ± 2 ºC/60% RH ± 5% RH.
FIGURE 4 - Sildenafil citrate content (%) variation on aqueous 
solutions (mean ± standard deviation; n = 3).  preservative-free 
solution stored at 5 ºC ± 3 ºC and  stored at 25 ºC ± 2 ºC/60% 
RH ± 5% RH  solution containing preservative stored at 5 ºC 
± 3 ºC and  stored at 25 ºC ± 2 ºC/60% RH ± 5% RH.
FIGURE 5 - Sildenafil citrate content (%) variation on syrup 
solutions (mean ± standard deviation; n = 3).  preservative-free 
solution stored at 5ºC ± 3ºC and  stored at 25 ºC ± 2 ºC/60% 
RH ± 5% RH  solution containing preservative stored at 5 ºC 
± 3 ºC and  stored at 25 ºC ± 2 ºC/60% RH ± 5% RH.
percentages of sildenafil citrate content were 98.31 ± 2.65 
and 98.97 ± 0.99 at 25 ºC and 5 ºC, respectively (Figure 5).
Microbiological stability
At the end of stability testing, all preparations were 
in accordance with EP’s Microbiological Quality of 
Pharmaceutical Preparations, i.e., there was an absence 
of Escherichia coli, and the total viable aerobic count 
were below 103 bacteria and not more than 102 fungi per 
gram or per millilitre. Neither preservative-free solutions 
nor solutions containing preservative exhibited the 
development of microorganisms in storage conditions at 
25 ºC and 5 ºC. This indicates that there is no advantage 
in using preservatives in these formulations.
In-use stability
Because we suggest a multi-dose immediate 
container, it was necessary to determine the stability of 
the preparations once the container is open. These studies 
were carried out on preservative-free solutions. Containers 
of aqueous and syrup solutions were opened twice a day 
at the hospital and at home. A 1-mL sample was removed 
from each preparation to simulate real conditions of 
use. This procedure occurred over 10 consecutive days 
for aqueous solutions and 14 days for syrup solutions; 
physicochemical and microbiological parameters were 
then determined.
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Physicochemical stability
The results demonstrate that both solutions remained 
unchanged in appearance, pH, and active ingredient 
content (Table I) in both simulation conditions.
Microbiological stability
In solutions that both contained preservative and 
solutions that were preservative-free, which were either 
stored at home or at the hospital, it was determined that 
microbial contamination, according to EP and the results 
of this study, demonstrated the absence of Escherichia 
coli. The results of microbial contamination expressed as 
total aerobic viable counts showed 40 cfu/mL for aqueous 
solutions stored at the hospital and no development 
of colonies in aqueous solutions stored at home or in 
syrup solutions used at home or in the hospital. In syrup 
solutions, the high level of sucrose plays an antimicrobial 
role. Although some development of germs was observed, 
in aqueous solutions used at the hospital, the values 
were much lower than the test limit present in the EP 
specifications.
DISCUSSION
Although excipients should be pharmacologically 
inactive, they may indeed cause adverse effects. It is 
important to consider that the physiology of neonates and 
infants differs considerably from that of adults. They may 
not be able to metabolise or eliminate an ingredient in a 
pharmaceutical product in the same manner as an adult 
(EMEA, 2006). It is common pharmacy practice when 
compounding extemporaneous oral liquid preparations 
from a commercially available solid oral dosage form for 
a paediatric patient who crushed tablets or the contents of 
a capsule are solubilised or suspended by the addition of 
water or juice. However, there are often limited data to 
support the stability or bioavailability of the final liquid 
dosage form and the potential interactions between the 
excipients subjected to those procedures (Glass, 2006).
During this study, sildenafil citrate solutions were 
kept as simple as possible and were prepared from pure 
active ingredients rather than from commercial tablets to 
avoid potential undesirable effects due to excipients.
Antioxidants and antimicrobial preservatives 
are ingredients that are used to increase the stability of 
medicines by retarding the oxidation of active ingredients 
and excipients or by reducing microbial proliferation. 
Certain chemical groups that make up the properties of these 
ingredients are usually aggressive towards living cells and 
lead to certain risks when used in humans. If these additional 
ingredients are not needed, then they should be avoided 
(CPMP, 2003b). Given this fact, we have prepared two very 
simple solutions: an aqueous solution and a syrup solution 
of sildenafil citrate without preservatives. Nonsterile liquid 
formulations are easily contaminated by microbial agents, 
and we know that nosocomial infections are significant 
causes of mortality in newborns and infants who require 
intensive care. This evidence justifies the inclusion of 
preservatives in test formulations. Propylparaben and 
methylparaben are stable compounds that have been used as 
antimicrobial preservatives in foods, drugs, and cosmetics 
for over 50 years. The association of methylparaben and 
propylparaben promotes a better antimicrobial action (Soni, 
2001,2002). Both the solutions containing preservatives 
and the preservative-free solutions retained their potency 
during the three months of the stability study. Appearance 
and pH values also remained unchanged. At the end of the 
stability study, no microbiological contamination was found 
in either solutions containing preservatives or preservative-
free solutions, at 5 ºC or 25 ºC, showing that sildenafil 
citrate aqueous and syrup solutions are chemically and 
microbiologically stable.
In-use stability tests were designed to detect the 
stability of preservative-free solutions in real conditions 
of use after first vial opening. In those samples stored at 
the hospital, microbial growth (40 cfu/mL) was detected 
in aqueous solutions; however, this value is below 
pharmaceutical specifications. In the syrup solutions, no 
TABLE I - Results of physicochemical determinations after in-use stability studies
Tests
Aqueous Solution Syrup Solution
Home Hospital Home Hospital
Observation Colourless limpid 
solution, with a slight 
bitter taste
Colourless limpid 
solution, with a slight 
bitter taste
Yellowish limpid 
solution, with a sweet 
taste
Yellowish limpid 












pH 4.06 3.97 4.28 4.27
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microbiological contamination was detected in either those 
samples used at home or at the hospital. Although these are 
promising results, the authors recommended that after the 
first use, the preparations should be stored in a refrigerator.
CONCLUSION
The results of this study indicate that sildenafil citrate 
is stable in both aqueous and syrup solutions without 
preservatives when packed in an amber glass bottle at both 
25 ºC and at 5 ºC for 91 days. Based on these results, a 
3-month shelf life can be assigned for these preparations. 
The studied formulations are very simple, containing only 
water or simple syrup as a vehicle, which is very important 
when formulations are created for paediatric use. When the 
vial is first opened, its contents are exposed to atmospheric 
oxygen and microbial invasion. In-use stability studies 
indicated that preparations of aqueous solutions could be 
used within 10 days, and syrup solutions could be used 
within 14 days after first use.
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